Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B12 and Active-B12® (holotranscobalamin) in the diagnosis of vitamin B12 deficiency

Author:

Murphy Michael J1ORCID,Brandie Fiona2,Ebare Mildred3,Harrison Michelle4,Dow Ellie1,Bartlett William A5,Craig David6

Affiliation:

1. Department of Biochemical Medicine, Ninewells Hospital & Medical School, Dundee, UK

2. Department of Biochemistry, Aberdeen Royal Infirmary, Aberdeen, UK

3. General Practice Training, NHS Education Scotland, Dundee, UK

4. Department of Haematology, Ninewells Hospital & Medical School, Dundee, UK

5. NHS National Services Scotland, Edinburgh, UK

6. Axis Shield Diagnostics Ltd, Dundee, UK*

Abstract

Background Assessing the pre- and post-test probability of disease in the context of routine health care is challenging. We wished to study how test performance parameters relating to clinical utility vary by clinical indication in a ‘real-world’ setting. Methods The diagnostic accuracy of serum total B12 and Active-B12® (holotranscobalamin) was evaluated in a primary care population, using serum methylmalonic acid as the reference standard. We used electronic requesting to establish the clinical indication for each request. Routine requests from primary care for serum total B12 were included if creatinine was also measured and estimated glomerular filtration rate was at least 60 mL/min/1.73 m2. Results Clinical indications included peripheral neuropathy ( n = 168), anaemia ( n = 168), cognitive decline ( n = 125), suspected dietary deficiency ( n = 76), other ( n = 362). For peripheral neuropathy, the area under the receiver operator curve ± 95% confidence interval (AUC ± CI) was 0.63 (0.54–0.71) ( P = 0.002) for total B12 and 0.68 (0.60–0.77) ( P < 0.0001) for Active-B12®. For anaemia, AUC ± CI was 0.56 (0.47–0.66) ( P = 0.10) for total B12 and 0.69 (0.59–0.78) ( P < 0.0001) for Active-B12®. For cognitive decline, AUC ± CI was 0.54 (0.43–0.65) ( P = 0.26) for total B12 and 0.69 (0.58–0.80) ( P = 0.0002) for Active-B12®. The pre–post-test change in probability of disease varied by clinical indication. Conclusion Combining diagnostic accuracy studies and electronic testing in a ‘real-world’ setting allows clinical utility to be assessed by clinical indication. Wider application of this would permit more personalised laboratory medicine. In this study, diagnostic performance of total B12 and Active-B12® varied across all indications. Active-B12® provided better discrimination, but this may have reflected the cut-offs used.

Publisher

SAGE Publications

Subject

Clinical Biochemistry,General Medicine

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Vitamin B12 – a scoping review for Nordic Nutrition Recommendations 2023;Food & Nutrition Research;2023-11-08

2. Vitamin B12 reference intervals on Beckman, Roche and Siemens analytical platforms;Annals of Clinical Biochemistry: International Journal of Laboratory Medicine;2023-09-12

3. Preliminary evaluation of the diagnostic performance of Roche Elecsys® active vitamin B12 versus total vitamin B12 for vitamin B12 deficiency screening;Annals of Clinical Biochemistry: International Journal of Laboratory Medicine;2023-08-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3